Autologous glioma cell vaccine with IL-4 gene transfected fibroblasts for malignant gliomas
Author Information
Author(s): Okada Hideho, Lieberman Frank S, Walter Kevin A, Lunsford L Dade, Kondziolka Douglas S, Bejjani Ghassan K, Hamilton Ronald L, Torres-Trejo Alejandro, Kalinski Pawel, Cai Quan, Mabold Jennifer L, Edington Howard D, Butterfield Lisa H, Whiteside Theresa L, Potter Douglas M, Schold S Clifford Jr, Pollack Ian F
Primary Institution: University of Pittsburgh School of Medicine
Hypothesis
Can vaccinations using autologous glioma cells and interleukin-4 gene transfected fibroblasts improve outcomes for patients with malignant gliomas?
Conclusion
The study suggests that while there are feasibility challenges in generating patient-specific vaccines, preliminary safety and immunological responses provide a rationale for further development of glioma vaccines.
Supporting Evidence
- Two participants in the first trial showed encouraging immunological and clinical responses.
- One participant demonstrated systemic T-cell responses against a glioma-associated antigen epitope.
- Five of six participants in the second trial received vaccinations with no major adverse events.
Takeaway
Doctors are trying to use a special vaccine made from a patient's own tumor cells to help fight brain cancer, and some patients showed good responses.
Methodology
Participants received surgeries to remove tumors, followed by vaccinations with autologous fibroblasts and glioma cells.
Limitations
The study faced challenges in generating sufficient vaccine cells in time for patients with rapidly progressing tumors.
Participant Demographics
Adult participants with recurrent or newly diagnosed glioblastoma multiforme or anaplastic astrocytoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website